TY - JOUR
T1 - Adoptive cell transfer
T2 - A clinical path to effective cancer immunotherapy
AU - Rosenberg, Steven A.
AU - Restifo, Nicholas P.
AU - Yang, James C.
AU - Morgan, Richard A.
AU - Dudley, Mark E.
PY - 2008/4
Y1 - 2008/4
N2 - Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
AB - Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged as the most effective treatment for patients with metastatic melanoma and can mediate objective cancer regression in approximately 50% of patients. The use of donor lymphocytes for ACT is an effective treatment for immunosuppressed patients who develop post-transplant lymphomas. The ability to genetically engineer human lymphocytes and use them to mediate cancer regression in patients, which has recently been demonstrated, has opened possibilities for the extension of ACT immunotherapy to patients with a wide variety of cancer types and is a promising new approach to cancer treatment.
UR - http://www.scopus.com/inward/record.url?scp=41149097574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41149097574&partnerID=8YFLogxK
U2 - 10.1038/nrc2355
DO - 10.1038/nrc2355
M3 - Review article
C2 - 18354418
AN - SCOPUS:41149097574
SN - 1474-175X
VL - 8
SP - 299
EP - 308
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 4
ER -